Novartis sued for $10M in unpaid bills; EU: Docs should stop prescribing Fabrazyme;

@FiercePharma: U.S. drug prices aren't sky-high, study finds. Article | Follow @FiercePharma

> A New York City-based medical marketing firm sued Novartis Pharmaceuticals alleging the drugmaker owes it $500,000 in unpaid fees for outstanding invoices, lost business revenues and damaged professional relationships. Story*

> In a blow to Genzyme, the European Union's chief drug regulator said doctors should not prescribe the company's Fabry disease drug to new patients, because of continuing shortages, and should use Shire's alternative Replagal instead. Report

> The EU has approved a new chewable form of cholesterol blockbuster Lipitor for children 10 and up with high levels of bad cholesterol and triglycerides. Report

> Bristol-Myers Squibb (BMY) got the EU nod for yet another indication of its arthritis medication Orencia, in combination with methotrexate, to be used as a first-line biologic after inadequate response other meds. Article

> Pharmaceutical companies are to strengthen cooperation with sports authorities to clamp down on the illegal use of medicines to enhance performance under a new agreement with the World Anti-Doping Agency. Report

> Irish drugmaker Elan said Dr. Eliseo Oreste Salinas will serve as company executive vice president and chief medical officer, effective immediately. Release

> Chinese drugmaker Biostar Pharmaceuticals said Tuesday it named Deyin "Bill" Chen as its new chief financial officer. Article

> Shire won FDA approval for its ADHD treatment Daytrana to be used for teens age 13 to 17. Link

Biotech News

@FierceBiotech: Sanofi's rumored buyout plans inspire guessing game. Article  | Follow @FierceBiotech
 
@JohnCFierce: Bad year for Xenoport, which had to slash its staff by 50% after the FDA rejected its drug for RLS. Now same drug flunks migraine study. Follow @JohnCFierce

> Roche files BLA for breakthrough T-DM1 cancer therapy. Story

> XenoPort's lead program suffers another big setback. Item

> Venrock gets lean and mean with $350M venture fund. News

> AlloCure taps Brenner as president, CEO. Article

Medical Device News

> FDA approves implantable mini telescope for AMD patients. Report

> Device firms among those looking to solve "garbage problem." Story

> Medtronic unit gets warning letter. Article

> EyeTechCare lands $9.5M for glaucoma device development. News

> Group highlights medical device security risks. Item

> Merit Medical creates 100 jobs in plant expansion. Report

> Samsung takes on med devices with blood test. Story

Drug Delivery News

> New 'smart bomb' tech used to target cancer cells. Article

> Researchers investigate potential of nano-sand. News

> Team looks to microbubbles for cancer drug delivery. Item

> Australian researchers nab grant for dendrimer delivery work. Story

And Finally... President Obama will bypass the Senate to appoint Dr. Donald Berwick to head up the federal Medicare and Medicaid health insurance programs. Report

*This item incorrectly stated that Novartis was being sued for $10 million instead of $500,000.

Suggested Articles

Teva is reportedly going for a moonshot with a $15 billion drug offer to settle its opioid cases. It's a plan that might just work, one analyst said.

CSL has sued a former exec who its says stole thousands of key documents as he left for competitor Pharming.

Influential U.S. cost watchdog ICER gave its blessing to Johnson & Johnson and Amarin's CV drugs. But there's a big catch for both meds.